Fulvestrant

In this video, Aruna Padmanabhan, MD, discusses the evaluation of PI3K inhibitor combinations as first-line treatment for patients with metastatic breast cancer.

CHICAGO — The addition of abemaciclib to fulvestrant extended PFS for patients with advanced breast cancer whose disease progressed on prior cyclin-dependent kinase 4/6 inhibitor therapy, according to data presented at ASCO Annual Meeting.

Healio spoke with Paolo Tarantino, MD, about FDA approvals in metastatic breast cancer.

SAN ANTONIO — The combination of zanidatamab, palbociclib and fulvestrant yielded promising PFS results among adults with HER2-positive/hormone receptor-positive metastatic breast cancer, findings from a phase 2A study showed.

An analysis of global conversations involving more than 1,600 health care professionals on social media in November has revealed collective optimism in response to the approval of a new weight-management option for adults with obesity.

SAN ANTONIO — The addition of either fulvestrant or letrozole to palbociclib conferred similar efficacy among patients with HER2-negative advanced breast cancer, according to data presented at San Antonio Breast Cancer Symposium.

The FDA approved capivasertib as part of combination therapy for certain patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer.

The FDA announced several regulatory actions the past few weeks.

A regimen of fulvestrant plus capivasertib may be effective in a subset of patients with breast cancer, according to results from the CAPItello-291 trial presented at San Antonio Breast Cancer Symposium.

In this video, Sara M. Tolaney, MD, MPH, discusses recent findings examining the use of capivasertib and fulvestrant in patients with aromatase inhibitor-resistant hormone receptor-positive, HER2-negative advanced breast cancer.